1 Biotech With Room to Run

Before you go, we thought you'd like these...
Before you go close icon

This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

In this edition, David takes a closer lok at Affymax, which just saw approval for Omontys, its anemia drug for patients on dialysis. Can Omontys steal significant share of this multibillion-dollar market with its aggressive pricing scheme despite the heavyweights in the industry? Keep watching, and find out about another company poised to profit from Omontys' success.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time this article was published David Williamson and The Motley Fool own shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading